08:16 AM EDT, 09/19/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Thursday its allogeneic cell therapy, ADI-001, demonstrated complete CD19+ B cell depletion in secondary lymphoid tissue during the phase 1 GLEAN trial.

The data also showed notable chimeric antigen receptor, or CAR, T cell activation and high levels of ADI-001 in tissues, reinforcing its potential as a best-in-class therapy for autoimmune diseases, the company said.

Shares of the company rose 5.5% in recent premarket activity.

Price: 1.5400, Change: +0.08, Percent Change: +5.48